• antiSMASH: on the hunt for new antibiotics

    Online tool antiSMASH is being used by scientists on the hunt for interesting bacterial metabolites with potential uses for creating new antibiotics, and its accompanying database was recently updated to...

  • Developing a new class of cancer combo drugs

    Cybrexa, a spin-out company from Yale University, is developing a new class of cancer therapeutics, looking to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity...

  • November’s top stories

    Sobi has signed agreements to acquire the rights to AstraZeneca’s Synagis medicine in the US for an upfront payment of $1.5bn, and Takeda Pharmaceutical has received a conditional approval from...

Go Top